^
Association details:
Biomarker:Chr t(14;20)
Cancer:Multiple Myeloma
Regimen:Isa-KRd (carfilzomib + dexamethasone injection + lenalidomide + Sarclisa (isatuximab-irfc))
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
New
Source:
Title:

3239 A Phase II Study of Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Isatuximab in Newly Diagnosed, Transplant-Eligible Multiple Myeloma (The SKylaRk Trial)Clinically Relevant Abstract

Published date:
11/03/2022
Excerpt:
For maintenance, patients were stratified based on cytogenetics (high-risk cytogenetics included deletion 17p, gain of 1q, and translocations t(4:14), t(14;16), t(14;20))….Of the 47 patients evaluable for response after 4 cycles, the ORR was 100% and 89% (42/47) achieved a very good partial response (VGPR) or better and 40% (19/47) a CR....Early data suggest that Isa-KRd induces deep responses in patients with NDMM.
Trial ID: